Frank Lee, Forma Therapeutics CEO
September 1, 2022 09:34 AM EDTUpdated 11:22 AM
Deals
Pharma

As No­vo Nordisk be­gins PhII sick­le cell tri­al, it snags a lat­er-stage blood dis­or­der drug in $1.1B For­ma buy

Kyle LaHucik

Senior Reporter

A few weeks af­ter of­fload­ing a can­cer drug un­der re­view at the FDA, For­ma Ther­a­peu­tics is pack­ing up the rest of its be­long­ings and head­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times